Document is current
Any future updates will be listed below
-
Authors
Ishibashi, Toru https://orcid.org/0000-0003-3383-9980
Shimizu, Ryosuke https://orcid.org/0000-0001-9666-8678
Kubota, Ryuji https://orcid.org/0000-0003-1979-4472
- License Information
-
More Information
Article History
Accepted: 23 October 2024
First Online: 20 November 2024
Declarations
:
: This study was funded by Shionogi & Co., Ltd.
: All authors are employees of Shionogi & Co., Ltd.
: The study was approved by Council for International Organizations of Medical Sciences International ethical guidelines and conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for good clinical practice. The SCORPIO-SR study (Phase 2/3 study of S-217622) was conducted in Japan with the approval of the ethics committee of a Japanese medical institution. Please see the Japanese registry site below.
: All participants gave their written informed consent for participation in the study.
: Not applicable.
: Shionogi & Co, Ltd is committed to disclosing the synopses and results of its clinical trials and sharing the clinical trial data with researchers on reasonable request. For further details, please refer to the websites of Shionogi & Co, Ltd () and Vivli ().
: The code cannot be made public because it is a macro linked to our internal system.
: Conceptualization: TI, RS, RK. Methodology: TI, RS, RK. Formal analysis: TI, RS. Investigation: TI, RS, RK. Interpretation: TI, RS, RK. Writing: TI, RS, RK.
